Telavancin
A once-daily vancomycin derivative with added membrane activity, approved for complicated skin infection and hospital-acquired pneumonia but carrying boxed warnings for kidney damage and fetal harm that have kept it a third-line drug.
Also known as lipoglycopeptide, telavancin hydrochloride, Vibativ, TD-6424
Approved drug — Licensed by a major regulator for human use, with phase-3 trial data behind it.
FDA-approved in 2009 for complicated skin infection on the ATLAS trials and in 2013 for hospital-acquired pneumonia on the ATTAIN trials, all non-inferiority designs against vancomycin. It is non-inferior, not superior, and it carries two boxed warnings vancomycin does not — which is why it sits well down most treatment algorithms.
How it works
Telavancin is vancomycin with two additions: a hydrophobic decylaminoethyl chain and a hydrophilic phosphonomethyl aminomethyl group. The lipophilic tail anchors the molecule in the bacterial membrane and gives it a second, vancomycin-independent killing mechanism through membrane depolarisation and increased permeability, producing faster and more complete bactericidal activity. The hydrophilic group was added to reduce tissue accumulation and improve renal handling, though nephrotoxicity remained the drug's defining problem. Like oritavancin it interferes with phospholipid-dependent coagulation assays. It also causes foamy urine and interferes with qualitative urine protein tests. In the HAP/VAP programme, patients with pre-existing moderate to severe renal impairment had higher mortality on telavancin than on vancomycin, which produced the boxed warning that shapes its use.
Targets: Lipid II D-Ala-D-Ala terminus, Bacterial cytoplasmic membrane, Peptidoglycan transglycosylase
Dosing
| Protocol | Dose | Frequency | Route |
|---|---|---|---|
| Complicated skin infection or hospital-acquired pneumoniaInfused over 60 minutes. | 10 mg / kgscales with body weight | once every 24 hours | intravenous |
| Renal impairment dosingOnce daily or every other day depending on creatinine clearance. | 7.5 mg – 10 mg / kgscales with body weight | every 24 to 48 hours | intravenous |
- · Dose figure is per kilogram: 10 mg/kg of actual body weight every 24 hours — about 750 mg for a 75 kg adult. Skin infection courses run 7-14 days, pneumonia 7-21 days.
- · 7.5 mg/kg every 24 hours for CrCl 30-50 mL/min, and 10 mg/kg every 48 hours for CrCl 10-29 mL/min. In HAP/VAP, telavancin should be avoided altogether when baseline CrCl is under 50 mL/min because of the observed excess mortality.
Titration
Doses are set by creatinine clearance and reassessed as renal function changes, which it frequently does on this drug.
Cycling
Treatment courses of 7-21 days depending on indication. Longer exposure raises the nephrotoxicity risk.
Pharmacology
- Half-life
- About 8 hours in adults with normal renal function, supporting once-daily dosing.
- Onset
- Rapid bactericidal activity; clinical response assessed over 48-72 hours.
- Routes
- intravenous
- Molecule
- Semi-synthetic lipoglycopeptide derived from vancomycin
- Sequence length
- 7 amino acids
- Molecular weight
- 1755.6 Da
Handling
- Diluent
- Sterile water for injection or 5% dextrose, then diluted for infusion
- Typical mix
- 15 or 45 mL
- Vial sizes
- 250, 750 mg
- Lyophilised
- Refrigerated at 2-8°C.
- Reconstituted
- Used within 4 hours at room temperature or 72 hours refrigerated, counting from the time of reconstitution.
Mixing
A 250 mg vial takes 15 mL and a 750 mg vial takes 45 mL, giving 15 mg/mL. Reconstitution can take several minutes — swirl until fully dissolved. Dilute to 0.6-8 mg/mL for infusion.
Side effects
- very commonTaste disturbance— A metallic or soapy taste affects roughly a third of patients and is quite characteristic of this drug.
- very commonNausea and vomiting
- commonNephrotoxicity— Boxed warning. New or worsening renal impairment occurred more often than with vancomycin, and in HAP/VAP patients with pre-existing renal impairment mortality was higher on telavancin.
- commonFoamy urine— Caused by the excipient hydroxypropyl-beta-cyclodextrin; harmless but alarming to patients who are not warned.
- commonInterference with coagulation tests— Falsely prolongs PT/INR, aPTT and activated clotting time. Draw samples immediately before the next dose to minimise it.
- uncommonQTc prolongation— Modest but real; matters in patients on other QT-prolonging drugs.
- rareFetal developmental toxicity— Boxed warning based on limb and digit malformations in three animal species. Women of childbearing potential need a negative pregnancy test before dosing.
Do not use if
- Pregnancy, unless no alternative exists — boxed warning for fetal risk based on animal teratogenicity.
- Concurrent intravenous unfractionated heparin sodium, a labelled contraindication because of coagulation assay interference.
- Hospital-acquired pneumonia with baseline CrCl below 50 mL/min, where mortality was higher than with vancomycin.
- Known hypersensitivity to telavancin.
Combining it
- conflictunfractionated heparin — Contraindicated together because aPTT monitoring becomes unreliable.
- cautionnephrotoxic drugs — NSAIDs, ACE inhibitors, loop diuretics, aminoglycosides and contrast all compound the renal risk.
- cautionQT-prolonging drugs — Additive QTc effect with agents such as amiodarone, fluoroquinolones and azoles.
- redundantvancomycin — Telavancin is a vancomycin derivative; there is no rationale for combining them.
What to monitor
- · Serum creatinine at baseline, then every 48-72 hours and at the end of therapy.
- · Pregnancy test before the first dose in women of childbearing potential.
- · ECG for QTc in patients on other QT-prolonging drugs or with electrolyte disturbance.
- · Draw coagulation samples just before the next dose, and use anti-Xa rather than aPTT if heparin is unavoidable.
Legal status
Prescription-only injectable, approved in the US. EU marketing authorisation was granted in 2011 and later withdrawn for commercial reasons.
References
- Stryjewski et al. 2008, ATLAS 1 and 2 trials of telavancin for complicated skin infection (trial)
- Rubinstein et al. 2011, ATTAIN trials of telavancin for hospital-acquired pneumonia (trial)
- Vibativ (telavancin) US prescribing information with boxed warnings (label)
Mechanism in depth
A lipoglycopeptide with dual action - D-Ala-D-Ala binding plus membrane depolarisation via its lipophilic side chain. More potent than vancomycin in vitro, but the safety profile has restricted its use considerably.
What usually goes wrong
It is chosen for potency and then causes the problems vancomycin was being avoided for. Nephrotoxicity is worse, not better, and the coagulation assay interference of the lipoglycopeptide class applies here too. In practice it is a later-line agent for that reason.
Bloodwork worth running
| Marker | When | Why it matters |
|---|---|---|
| Serum creatinine | Baseline then every 2-3 days. | Nephrotoxicity is more frequent than with vancomycin and carries a boxed warning; outcomes were worse in patients with pre-existing renal impairment.Act if: Pre-existing moderate renal impairment is a relative contraindication. |
| ECG QTc | Baseline in patients with cardiac risk factors. | Telavancin prolongs QTc and should be avoided alongside other QT-prolonging drugs.Act if: QTc above 500 ms warrants reconsideration. |
| Pregnancy test | Before the first dose. | Developmental toxicity in multiple animal species led to a boxed warning; pregnancy must be excluded before use in women of childbearing potential.Act if: A positive test contraindicates the drug. |
Pharmacokinetics
- Protein binding
- 90%
- Crosses blood-brain barrier
- no
- Elimination
- Renal
Receptor targets
- D-Ala-D-Ala terminus and bacterial membrane — Dual-mechanism
Cell wall inhibition and membrane depolarisation
What to expect, and when
Once-daily dosing with rapid concentration-dependent killing.
Genuinely uncertain
- Whether its in vitro potency advantage translates to any clinical benefit that offsets the toxicity is not demonstrated.